Activ'Inside publishes study validating cognitive advantages of extract

Published: 22-Jun-2023

Memophenol has been supported by gold standard clinical studies that demonstrate the effectiveness of the patented formula in combating cognitive ageing

Activ’Inside, supplier of science-backed food supplements, has revealed the results of its latest clinical trial, further validating the cognitive advantages of Memophenol, a patented polyphenol-rich grape and blueberry extract.

Memophenol, the outcome of a rigorous four-year international research program, Neurophenol, has been supported by gold standard clinical studies that demonstrate the effectiveness of the patented formula in combating cognitive ageing. The formula's pharma-like development, has been widely covered, including a feature in the Journal of the American Medical Association (JAMA).

Prior studies have showcased the efficacy of Memophenol at a dosage of 600mg, exhibiting notable improvements in memory after a chronic supplementation and cognitive performances after 90 minutes. In addition, existing literature studies have shown the efficacy of flavanol monomers in improving cerebral blood flow, associated with better cognitive performance, at a dose contained in only 300mg of Memophenol.

Motivated by these findings, Activ’Inside undertook its clinical trial to explore the effects of a lower dosage of 300mg on older adults with Mild Cognitive Impairment (MCI).

The clinical trial followed a robust two-arm, parallel-group, randomised, double-blind, placebo-controlled design. Over a span of 24 weeks, 143 volunteers aged between 60 and 80, who self-reported difficulties with cognition, were administered either 150 mg of Memophenol twice daily or a placebo.

The participants underwent a battery of tests and questionnaires to evaluate their cognitive function at different time periods. The results of the study demonstrate significant cognitive benefits of Memophenol at the 300mg dosage.

"These groundbreaking studies provide compelling evidence for the cognitive benefits of Memophenol at different dosages," stated David Gaudout, Chief Innovations Officer at Activ’Inside. "The results validate our hypothesis that Memophenol, even at a reduced dosage of 300mg, can significantly enhance executive functions, speed of information processing, visuospatial episodic memory and learning, and reduce cognitive failures in older adults with MCI." 

With proprietary studies supporting its efficacy, Memophenol has health claims in multiple countries, cementing its position as a trusted and effective solution for cognitive support.

Activ’Inside remains steadfast in its commitment to pushing the boundaries of scientific research and innovation to develop exceptional food supplements that harness the power of natural ingredients for improved cognitive health and overall well-being.

Relevant companies

You may also like